title: [Clinical practice guidelines: Standards, Options and Recommendations for first line medical treatment of patients with ovarian neoplasms (summary report)].
abstract: BACKGROUND
  The "Standards, Options and Recommendations" (SOR) project, which started in 1993, is a collaboration between the French Federation of Cancer Centers (FNCLCC), the 20 French Regional Cancer Centers, and specialists from French public universities, general hospitals and private clinics. The main objective is the development of clinical practice guidelines to improve the quality of health care and the outcome of cancer patients.
  
  
  OBJECTIVE
  To update clinical practice guidelines for first line medical treatment of patients with ovarian neoplasms in collaboration with the French Society for Gynaecologica Oncology.
  
  
  METHODS
  The methodology is based on a literature review and critical appraisal by a multidisciplinary group of experts. The CPGs are defined following the definitions of the Standards, Options and Recommendations project. Once the guideline has been developed, the document is submitted for review by independent reviewers.
  
  
  RESULTS
  This article is a summary version of the full document presenting the clinical practice guidelines with algorithms. After surgery, most patients with ovarian neoplasms need adjuvant medical treatment. These guidelines concern the initial medical treatment (chemotherapy, hormone treatment and immunotherapy) and potential consolidation treatment. To complete the indications, two alternative treatment strategies are taken into account: no treatment and radiotherapy. This updated version concerns the indications and the modalities of chemotherapy. The main modifications are: 1) first-line chemotherapy for ovarian neoplasm can be taxane-platinum or carboplatine alone; 2) poly-chemotherapy is no longer a standard; 3) for early stages, except for stage IA grade I non-clear-cell tumours, adjuvant chemotherapy should be preferred to no treatment; 4) chemotherapy is standard for all stage III tumours, irrespective of the surgical result; 5) for stage IA G2-3 to IIA tumours, complete surgical staging and determination of the histological grade are standards.
authors.affiliation: Institut Gustave-Roussy, Villejuif, FRANCE.
authors.forename: Catherine
authors.initials: C
authors.lastname: Lhommé
authors.forename: Isabelle
authors.initials: I
authors.lastname: Ray-Coquard
authors.forename: Jean-Pierre
authors.initials: JP
authors.lastname: Guastalla
authors.forename: Anne
authors.initials: A
authors.lastname: Bataillard
authors.forename: Laurence
authors.initials: L
authors.lastname: Thomas
authors.forename: Pascal
authors.initials: P
authors.lastname: Bonnier
authors.forename: Daniel
authors.initials: D
authors.lastname: Dargent
authors.forename: Nicole
authors.initials: N
authors.lastname: Dohollou
authors.forename: Gérard
authors.initials: G
authors.lastname: Ganem
authors.forename: Jean-Pierre
authors.initials: JP
authors.lastname: Lefranc
authors.forename: Jean-Louis
authors.initials: JL
authors.lastname: Misset
authors.forename: Olivier
authors.initials: O
authors.lastname: Rixe
authors.forename: Xavier
authors.initials: X
authors.lastname: Tchiknavorian
authors.forename: Christophe
authors.initials: C
authors.lastname: Tournigand
authors.forename: Richard
authors.initials: R
authors.lastname: Villet
authors.forename: Thomas
authors.initials: T
authors.lastname: Bachelot
authors.forename: Pierre
authors.initials: P
authors.lastname: Kerbrat
authors.forename: Béatrice
authors.initials: B
authors.lastname: Fervers
authors.forename: Jean-Pierre
authors.initials: JP
authors.lastname: Basuyau
authors.forename: Christine
authors.initials: C
authors.lastname: Cohen-Solal-Le Nir
authors.forename: Philippe
authors.initials: P
authors.lastname: Morice
authors.forename: Pierre
authors.initials: P
authors.lastname: Duvillard
authors.forename: Eric
authors.initials: E
authors.lastname: Voog
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use; D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use; D001500:BCG Vaccine / Q000627:therapeutic use; D003663:Decision Trees; D005260:Female; D006801:Humans; D010051:Ovarian Neoplasms / Q000188:drug therapy / Q000532:radiotherapy / Q000628:therapy*; D013629:Tamoxifen / Q000627:therapeutic use
chemical_list: D000970:Antineoplastic Agents; D018931:Antineoplastic Agents, Hormonal; D001500:BCG Vaccine; D013629:Tamoxifen
vernacular_title: Recommandations pour la pratique clinique Standards, Options et Recommandations 2003 pour le traitement médical de première ligne des patientes atteintes de tumeurs épithéliales malignes de l'ovaire, mise à jour (rapport abrégé).